December 5, 2019 / 9:58 PM / 6 months ago

BRIEF-Fergene's Bladder Cancer Therapy Trial Meets Main Goal In Late-Stage Study

Dec 5 (Reuters) - Blackstone Group Inc:

* FERGENE ANNOUNCES PIVOTAL PHASE 3 STUDY OF NADOFARAGENE FIRADENOVEC MET ITS PRIMARY ENDPOINT WITH MORE THAN HALF OF PATIENTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (CIS ± TA/T1) ACHIEVING A COMPLETE RESPONSE AT THREE MONTHS

* FERGENE, A NEW GENE THERAPY COMPANY FORMED BY FERRING PHARMACEUTICALS AND BLACKSTONE LIFE SCIENCES, SAYS STUDY MET ITS PRIMARY ENDPOINT

* FERGENE SAYS STUDY CLINICAL RESULTS ALSO SUPPORT A FAVORABLE SAFETY AND TOLERABILITY PROFILE FOR NADOFARAGENE FIRADENOVEC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below